Abstract
Despite severe economic damage, full-service restaurants and bars have been closed in hopes of suppressing the spread of SARS-CoV-2 worldwide. This study explores whether the early closure of restaurants and bars in February 2021 reduced symptoms of SARS-CoV-2 in Japan. Using a large-scale nationally representative longitudinal survey, we found that the early closure of restaurants and bars decreased the utilization rate among young persons (OR 0.688; CI95 0.515?0.918) and those who visited these places before the pandemic (OR 0.754; CI95 0.594?0.957). However, symptoms such of SARS-CoV-2 did not decrease in these active and high-risk subpopulations. Among the more inactive and low-risk subpopulations, such as elderly persons, no discernible impacts are observed in both the utilization of restaurants and bars and the symptoms of SARS-CoV-2. These results suggest that the early closure of restaurants and bars without any other concurrent measures does not contribute to the suppression of SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grants (grant number 18H03062 and 21H04856, Dr.Takahiro Tabuchi, and 18K01632, Dr Aiura) and the Japan Agency for Medical Research and Development (AMED; grant number 2033648, Prof. Takeo Fujiwara).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of the Osaka International Cancer Institute (No. 20084).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
∗ This study was approved by the Institutional Review Board of the Osaka International Cancer In-stitute (No. 20084).This work was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grants (grant number 18H03062 and 21H04856, Dr.Takahiro Tabuchi, and 18K01632, Dr Aiura) and the Japan Agency for Medical Research and Development (AMED; grant number 2033648, Prof. Takeo Fujiwara).
Data Availability
Data are prohibited to be shared due to the confidential nature.
